AUTHOR=Cortinovis Diego L. , Canova Stefania , Abbate Marida , Colonese Francesca , Bidoli Paolo 

TITLE=Focus on Nivolumab in NSCLC

JOURNAL=Frontiers in Medicine

VOLUME=Volume 3 - 2016

YEAR=2016

URL=https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2016.00067

DOI=10.3389/fmed.2016.00067

ISSN=2296-858X

ABSTRACT=Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach of treating NSCLC using immunotherapy has still unsolved questions and challenging issues in regard to the optimal selection of the patient, its role in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immunomediated adverse events, and how to overcome the immunoresistance.